Chronic Obstructive Pulmonary Disease | Disease Landscape & Forecast | G7 | 2024
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are expected to have an impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years. Although physicians will welcome additional treatment options for this chronic disease as a result of the development of novel drug classes, including biologics (e.g., IL-33 inhibitors, IL-4/IL-13 inhibitors, and IL-5 inhibitors) and novel inhaled and nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue or halt disease progression.
Questions answered
- Will LABA/LAMA FDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICS FDCs threaten uptake of these agents?
- What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Trelegy, Advair, Breo; GSK / Innoviva’s Anoro; BI’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri, Symbicort)? What factors drive physicians’ treatment decisions?
- Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-5 inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
- How will the market evolve over the 10-year forecast period?
- What are the unmet needs for COPD?
Geography: United States, EU5, Japan
Primary research: 25 country-specific interviews with thought-leading pulmonologists; supported by survey data collected for this and other Clarivate research
Epidemiology: Number of drug-treated COPD patients by country, segmented by severity (mild to moderate, severe to very severe)
Forecast: 10-year, annualized, drug-level sales and patient share of key COPD therapies through 2033, segmented by brands / generics and epidemiological subpopulations (mild to moderate, severe to very severe)
Emerging therapies: Phase 3 / PR: 6 drugs; Phase 2: 8 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
